Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked conscientiously but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last few shares. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire job interview which I came away with a bad impression of the company.

Irony of irony, my poor viewpoint of the company has grown steadily, yet the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of this technology and linked intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) as well as the first brand new drug program approval ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it has this individual therapies as well as a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an active organization with diverse interests albeit focused on leronlimab, several disease types, multiple publications in addition to multiple delivering presentations.

Can all of it be smoke and mirrors? That is a question I’ve been asking myself with the very beginning of my interest in this particular organization. Judging by the multiples of thousands of several responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a classic battleground, or perhaps some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *